Your browser doesn't support javascript.
loading
Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
Tran, Phu N; Sheng, Jiansong; Randolph, Aaron L; Baron, Claudia Alvarez; Thiebaud, Nicolas; Ren, Ming; Wu, Min; Johannesen, Lars; Volpe, Donna A; Patel, Dakshesh; Blinova, Ksenia; Strauss, David G; Wu, Wendy W.
Afiliación
  • Tran PN; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Sheng J; Division of Immunology and Hematology Devices, Center for Devices and Radiological Health, US Food and Drug Administration. Silver Spring, Maryland, United States of America.
  • Randolph AL; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Baron CA; CiPALab, Gaithersburg, Maryland, United States of America.
  • Thiebaud N; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Ren M; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Wu M; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Johannesen L; Vertex Pharmaceuticals (Europe) Ltd, Abingdon, Oxfordshire, United Kingdom.
  • Volpe DA; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Patel D; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Blinova K; Division of Immunology and Hematology Devices, Center for Devices and Radiological Health, US Food and Drug Administration. Silver Spring, Maryland, United States of America.
  • Strauss DG; Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Wu WW; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
PLoS One ; 15(11): e0241362, 2020.
Article en En | MEDLINE | ID: mdl-33157550
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Buprenorfina / Bloqueadores de los Canales de Potasio / Electrocardiografía / Canales de Potasio Éter-A-Go-Go Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Buprenorfina / Bloqueadores de los Canales de Potasio / Electrocardiografía / Canales de Potasio Éter-A-Go-Go Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article